Amarin Corporation plc (AMRN)

NASDAQ: AMRN · IEX Real-Time Price · USD
0.866
+0.006 (0.74%)
At close: Apr 22, 2024, 4:00 PM
0.860
-0.006 (-0.65%)
After-hours: Apr 22, 2024, 4:47 PM EDT
0.74%
Market Cap 353.92M
Revenue (ttm) 306.91M
Net Income (ttm) -59.11M
Shares Out 408.82M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE 500.00
Dividend n/a
Ex-Dividend Date n/a
Volume 739,848
Open 0.863
Previous Close 0.859
Day's Range 0.860 - 0.885
52-Week Range 0.650 - 1.490
Beta 2.01
Analysts Sell
Price Target 1.08 (+24.76%)
Earnings Date May 1, 2024

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboratio... [Read more]

Sector Healthcare
IPO Date Apr 1, 1993
Employees 275
Stock Exchange NASDAQ
Ticker Symbol AMRN
Full Company Profile

Financial Performance

In 2023, AMRN's revenue was $306.91 million, a decrease of -16.87% compared to the previous year's $369.19 million. Losses were -$59.11 million, -44.13% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AMRN stock is "Sell." The 12-month stock price forecast is $1.08, which is an increase of 24.76% from the latest price.

Price Target
$1.08
(24.76% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Amarin Announces Results of Annual General Meeting of Shareholders

- Shareholders Approve Share Repurchase Program of up to $50 Million - - Shareholders Approve Share Repurchase Program of up to $50 Million -

16 hours ago - GlobeNewsWire

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, a...

7 days ago - GlobeNewsWire

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action

14 days ago - GlobeNewsWire

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American Col...

16 days ago - GlobeNewsWire

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039 Company's IP Protection for VAZKEPA® in Europe Now Extended Into 2039

19 days ago - GlobeNewsWire

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

-- Subgroup Analyses from REDUCE-IT ® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --    DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOB...

4 weeks ago - GlobeNewsWire

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 -- -- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash ...

7 weeks ago - GlobeNewsWire

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, an...

2 months ago - GlobeNewsWire

Amarin Chairman & CEO Issue Letter to Shareholders

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Chairman of the Board, Odysseas Kostas, M.D., and Presi...

3 months ago - GlobeNewsWire

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive Ca...

3 months ago - GlobeNewsWire

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amar...

4 months ago - GlobeNewsWire

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN): Sarissa believes Amarin's stock is si...

5 months ago - Business Wire

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease --

5 months ago - GlobeNewsWire

Amarin Reports Third Quarter 2023 Financial Results

-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Oper...

6 months ago - GlobeNewsWire

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

-- Provoost Brings More than 20 Years of Corporate Counsel Experience to Amarin -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today a...

6 months ago - GlobeNewsWire

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- -- Additional Mechanistic Data on Eicosape...

6 months ago - GlobeNewsWire

Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, an...

6 months ago - GlobeNewsWire

Amarin to Present at the 2023 Cantor Global Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is sc...

7 months ago - GlobeNewsWire

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

– Dutch Ministry of Health Approves VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease –

9 months ago - GlobeNewsWire

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

-- Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and ...

9 months ago - GlobeNewsWire

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high  cardiovascula...

9 months ago - GlobeNewsWire

Amarin Reports Second Quarter 2023 Financial Results

-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and Royalty Revenues, of Which $11...

9 months ago - GlobeNewsWire

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus' Established Commercial and Marketing Expertise in the Region Collaboration Broadens Reach of VAZKEPA to Additional...

9 months ago - GlobeNewsWire

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society...

9 months ago - GlobeNewsWire

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

-- Spain's Drug Pricing Committee recommends reimbursement of VAZKEPA® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular risk 1 -- -- Positive rec...

9 months ago - GlobeNewsWire